FDA Clears Biosense Webster Direct Contact Force Catheter Ablation Therapy
Biosense Webster Inc.’s Thermocool Smarttouch Catheter enables direct and real-time measurement of contact force during catheter ablation procedures for patients suffering from drug-resistant paroxysmal atrial fibrillation (Afib), sustained monomorphic ischemic ventricular tachycardia and Type I atrial flutter.
The Thermocool Smarttouch Catheter provides direct, real-time quantitative feedback graphically displayed on the company’s Carto 3 System upon tissue contact.
The U.S. Food and Drug Administration (FDA) approved Biosense Webster Inc.’s Thermocool Smarttouch Catheter in February 2014.
For more information: www.biosensewebster.com